SCHEMBL6967366

SCHEMBL6967366

CC(=O)NC(C(C)=O)C(C)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
CA2 P00918 1/20 0.39
PTGS1 P23219 1/20 0.39
MMP12 P39900 1/20 0.39
NFKB1 P19838 2/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
ALOX15 P16050 1/20 0.39
PTGS2 P35354 1/20 0.39
THPO P40225 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 4/20 0.37
CYP1A2 P05177 1/20 0.36
CRAT P43155 1/20 0.32
CRBN Q96SW2 1/20 0.32
LMNA P02545 2/20 0.31
TRPV1 Q8NER1 1/20 0.31
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9336407 0.85 KDM4E (0.44) KDM4ECA2PTGS1MMP12NFKB1
SCHEMBL4961544 0.81 SMN1; SMN2 (0.39) KDM4ECA2PTGS1MMP12NFKB1
SCHEMBL143910 0.78 KDM4E (0.48) KDM4ECA2PTGS1MMP12NFKB1
SCHEMBL6970706 0.78 FFAR3 (0.35) KDM4ECA2PTGS1MMP12NFKB1
SCHEMBL964570 0.75 LMNA (0.50) KDM4ECA2MAPTTHRBALOX15
SCHEMBL12959118 0.75 CRBN (0.41) CA2NFKB1ALOX15THPOBLM
SCHEMBL9614381 0.75 KDM4E (0.46) KDM4ECA2PTGS1MMP12NFKB1
SCHEMBL1471075 0.73 SMN1; SMN2 (0.42) KDM4ECA2PTGS1MMP12NFKB1
SCHEMBL9614376 0.73 CRAT (0.38) KDM4ECA2PTGS1MMP12NFKB1
SCHEMBL3869217 0.73 KDM4E (0.44) KDM4ECA2PTGS1MMP12NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964640-B2 Oligomers of straight-chain and unbranched fatty acids and drugs containing these PLT PATENT & LICENSE TRADING LTD. (GB) 2011-06-21 US disclosed
US-7964640-B2 Oligomers of straight-chain and unbranched fatty acids and drugs containing these PLT PATENT & LICENSE TRADING LTD. (GB) 2011-06-21 US disclosed
US-20090012166-A1 Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These PLT PATENT & LICENSE TRADING S.L. (ES) 2009-01-08 US disclosed
US-20090012166-A1 Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These PLT PATENT & LICENSE TRADING S.L. (ES) 2009-01-08 US disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP disclosed
US-3993656-A BRONCHODILATOR, HYPOTENSIVES MERCK & CO., INC. (US) 1976-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012166-A1 Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These FASN, FFAR3, FFAR2 KDM4E 4720/4885CA2 4330/4885PTGS1 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.